Pfizer to expand tests of COVID-19 vaccine in children below 12

New study to enroll thousands of children below 12 years at dozens of sites across the US, Finland, Poland and Spain.

Pfizer has said it will begin testing its COVID-19 vaccine in a larger group of children below 12 years of age after selecting a lower dose of the shot in an earlier stage of the trial. The study will enrol up to 4,500 children at more than 90 clinical sites in the United States, Finland, Poland and Spain, the pharma company said. The vaccine made by Pfizer and its German partner BioNTech is already authorised for emergency use in anyone 12 and older in the US, Canada and the European Union. They receive the same dose as adults: 30 micrograms.